SLC5A2 and chronic kidney disease: Understanding how ERAs individually and in combination with SGLT2 inhibitors influence fluid dynamics in patients with CKD can inform the optimal use of zibotentan in clinical practice and guide the use of this therapy in patients who benefit most with minimal risk of side effects.